Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis

• Published in: BJU international 2002-09, Vol.90 (4), p.442-445
• Main Authors: YeniçerioGlu, Y., Kefi, A., Aslan, G., Çavdar, C., Esen, A.A., Çamsari, T., Çelebi, I.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; dialysis; erectile dysfunction; Erectile Dysfunction - complications; Erectile Dysfunction - drug therapy; Genital system. Reproduction; Gynecology. Andrology. Obstetrics; Humans; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - therapy; Male; Male genital diseases; Medical sciences; Middle Aged; Non tumoral diseases; Patient Satisfaction; Peritoneal Dialysis; Pharmacology. Drug treatments; Phosphodiesterase Inhibitors - therapeutic use; Piperazines - therapeutic use; Prospective Studies; Purines; Quality of Life; Renal Dialysis; Sexual Behavior; sildenafil; Sildenafil Citrate; Sulfones
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1046/j.1464-410X.2002.02914.x

Objective  To assess the efficacy of sildenafil for erectile dysfunction (ED) in patients on haemodialysis (HD) or peritoneal dialysis (PD), as men with end‐stage renal disease (ESRD) often have sexual dysfunction (up to 82% among those on chronic dialysis). Patients and methods  Forty‐one patients with ED and in ESRD participated in an open‐label prospective study. Thirty patients on HD and 11 on PD were asked to complete the International Index of Erectile Function (IIEF) and Fugl‐Meyer life‐satisfaction scale before and after sildenafil treatment. A total score in the erectile function domain of ≤ 25 was accepted as indicating ED. All patients were started on a 25‐mg dose, which was increased to 50 mg if there was no response after two trials. In addition, the overall efficacy question was used to evaluate satisfaction, and patients reported any side‐effects during treatment. Results  The erectile function and intercourse satisfaction domains improved significantly in both groups ( P